Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants
Abstract Lorlatinib, a selective inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinase, is indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC) following progression on crizotinib and at least one other ALK inhibitor, or alecti...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2021-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|